碳酸镧咀嚼片联合醋酸钙片治疗维持性血液透析患者高磷血症的临床研究

发布时间：2018-06-07 16:03

本文选题：碳酸镧 + 醋酸钙　；参考：《中国临床药理学杂志》2017年16期

【摘要】：目的观察碳酸镧联合醋酸钙治疗维持性血液透析患者高磷血症的临床疗效。方法将70例维持性血液透析高磷血症患者随机分为试验组35例和对照组35例。对照组给予醋酸钙片,起始剂量为醋酸钙片667 mg,每日3次,口服;试验组在对照组的基础上给予碳酸镧咀嚼片250 mg,每日3次,口服。2组均治疗12周。评价2组患者的临床疗效及血磷、血钙、甲状旁腺素水平(iPTH),并观察2组的药物不良反应发生情况。结果治疗后,试验组降磷总有效率91.43%(32/35例),对照组为71.43%(25/35例),差异有统计学意义(P0.05)。治疗后,试验组血磷、血钙、iPTH分别为(1.73±0.16)mmol·L~(-1),(2.25±0.15)mmol·L~(-1),(189.60±68.49)pg·mL~(-1),对照组分别为(1.88±0.29)mmol·L~(-1),(2.45±0.19)mmol·L~(-1),(217.83±64.00)pg·mL~(-1),差异均有统计学意义(均P0.05)。试验组出现恶心呕吐2例,药物不良反应率为5.71%(2/35例);对照组出现腹痛1例,药物不良反应率为2.86%(1/35例);2组药物不良反应发生率差异无统计学意义(P0.05)。结论碳酸镧联合醋酸钙可有效治疗维持性血液透析患者高磷血症,且安全性较好。
[Abstract]:Objective to observe the clinical effect of lanthanum carbonate combined with calcium acetate on hyperphosphatemia in maintenance hemodialysis patients. Methods 70 patients with maintenance hemodialysis hyperphosphatemia were randomly divided into trial group (n = 35) and control group (n = 35). The control group was given calcium acetate tablets at the initial dose of 667 mg, 3 times a day, and the experimental group was given 250 mg of lanthanum carbonate chewable tablets, 3 times a day, on the basis of the control group, for 12 weeks. Objective: to evaluate the clinical efficacy, serum phosphorus, serum calcium and parathyroid hormone levels of iPTHG in two groups, and to observe the occurrence of adverse drug reactions in the two groups. Results after treatment, the total effective rate of reducing phosphorus was 91.43 / 32 / 35 in the experimental group and 71.43 / 25 / 35 in the control group. The difference was statistically significant (P 0.05). After treatment, the levels of serum phosphorus and calcium in the experimental group were 1.73 卤0.16)mmol / L ~ (-1) respectively, were 2.25 卤0.15)mmol / L ~ (-1) and 189.60 卤68.49)pg / mL ~ (-1), respectively, while those in the control group were 2.45 卤0.19)mmol / L ~ (-1) and 217.83 卤64.00)pg / mL ~ (-1), respectively (P < 0.05). There were 2 cases of nausea and vomiting in the trial group, the adverse drug reaction rate was 5.71% / 35 cases, in the control group, there was abdominal pain in 1 case, and the adverse drug reaction rate was 2.86% in 35 cases. There was no significant difference in the incidence of adverse drug reactions between the two groups (P 0.05). Conclusion Lanthanum carbonate combined with calcium acetate can effectively treat hyperphosphatemia in maintenance hemodialysis patients, and it is safe.
【作者单位】：金华市中心医院肾内科;
【基金】：浙江省卫生厅科研基金资助项目(2012KYB227)
【分类号】：R692.5

【相似文献】